Capsaicin-induced mucus secretion in rat airways assessed in vivo and non-invasively by magnetic resonance imaging

British Journal of Pharmacology

Volumn 150, Issue 8, 2007, Pages 1022-1030

  Karmouty Quintana, H ^a,b,d   Cannet, C ^a   Sugar, R ^c   Fozard, J R ^a   Page, C P ^b   Beckmann, N ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c NOVARTIS HORSHAM RESEARCH CENTRE   (United Kingdom)

^d MCGILL UNIVERSITY   (Canada)

Author keywords

Neurokinin; Non invasive; Sensory nerves; Spontaneously breathing; Tachykinins; TRPV 1

Indexed keywords

CAPSAICIN; CAPSAZEPINE; CROMOGLYCATE DISODIUM; DNK 333; N [1 (3,4 DICHLOROBENZYL) 3 (2 OXOAZEPAN 3 YL)CARBAMOYL]ALLYL N METHYL 3,5 BIS(TRIFLUOROMETHY)BENZAMIDE; TACHYKININ RECEPTOR ANTAGONIST; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRONCHUS SECRETION; CONTROLLED STUDY; DRUG EFFECT; GOBLET CELL; IN VIVO STUDY; LUNG LAVAGE; MALE; NERVE STIMULATION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RAT; SENSORY NERVE;

ANIMALS; AZA COMPOUNDS; BENZAMIDES; BRONCHOALVEOLAR LAVAGE FLUID; CAPSAICIN; CROMOLYN SODIUM; GOBLET CELLS; LUNG; MAGNETIC RESONANCE IMAGING; MALE; MUCUS; NEURONS, AFFERENT; RATS; RATS, INBRED BN; RECEPTORS, NEUROKININ-1; RECEPTORS, NEUROKININ-2; TIME FACTORS; TRPV CATION CHANNELS;

EID: 34247279786     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/sj.bjp.0707168     Document Type: Article

References (48)

1. Barnes PJ (2001). Related Neurogenic inflammation in the airways. Respir Physiol 125: 145-154.
2. Beckmann N, Tigani B, Ekatodramis D, Borer R, Mazzoni L, Fozard JR (2001). Pulmonary edema induced by allergen challenge in the rat: noninvasive assessment by magnetic resonance imaging. Magn Reson Med 45: 88-95.
3. Beckmann N, Tigani B, Sugar R, Jackson AD, Jones G, Mazzoni L, Fozard JR (2002). Noninvasive detection of endotoxin-induced mucus hypersecretion in rat lung by MRI. Am J Physiol Lung Cell Mol Physiol 283: L22-L30.
4. Bevan S, Hothi S, Hughes G, James IF, Rang HP, Shah K, Walpole CS, Yeats JC (1992). Capsazepine: a competitive antagonist of the sensory neurone excitant capsaicin. Br J Pharmacol 107: 544-552.
5. Biggs DF, Goel V (1985). Mechanisms of action of sodium cromoglycate. Can J Physiol Pharmacol 63: 760-765.
6. Biro T, Maurer M, Modarres S, Lewin NE, Brodie C, Acs G, Acs P, Paus R, Blumberg PM (1998). Characterization of functional vanilloid receptors expressed by mast cells. Blood 91: 1332-1340.
7. Buck SH, Burks TF (1986). The neuropharmacology of capsaicin: review of some recent observations. Pharmacol Rev 38: 179-226.
8. Caterina MJ, Schumacher MA, Tominaga M, Rosen TA, Levine JD, Julius D (1997). The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature 389: 816-824.
9. Collier JG, Fuller RW (1984). Capsaicin inhalation in man and the effects of sodium cromoglycate. Br J Pharmacol 81: 113-117.
10. Delgado AV, McManus AT, Chambers JP (2003). Production of tumor necrosis factor-alpha, interleukin 1-beta, interleukin 2, and interleukin 6 by rat leukocyte subpopulations after exposure to substance P. Neuropeptides 37: 355-361.
11. Dixon CM, Barnes PJ (1989). Bradykinin-induced bronchoconstriction: inhibition by nedocromil sodium and sodium cromoglycate. Br J Clin Pharmacol 27: 831-836.
12. Fozard JR, Baur F, Wolber C, Collingwood SP (2001). Inhibition by viozan of extravasation induced in rat trachea by capsaicin is mediated exclusively by beta 2-adrenoceptors. Naunyn Schmiedebergs Arch Pharmacol 364: 570-572.
13. Germonpre PR, Joos GF, Everaert E, Kips JC, Pauwels RA (1995). Characterization of neurogenic inflammation in the airways of two highly inbred rat strains. Am J Respir Crit Care Med 152: 1796-1804.
14. Gerspacher M, Lewis C, Ball HA, Howes C, Subramanian N, Ryffel K, Fozard JR (2003). Stereoselective preparation of N-[(R,R)-(E)-1-(3,4-dichlorobenzyl)-3- (2-oxoazepan-3-yl)carbamoyl]allyl-N-methyl-3,5 bis(trifluoromethyl)benzamide, a potent and orally active dual neurokinin NK(1)/NK(2) receptor antagonist. J Med Chem 46: 3508-3513.
15. Holzer P (1991). Capsaicin: cellular targets, mechanisms of action, and selectivity for thin sensory neurons. Pharmacol Rev 43: 143-201.
16. Joos GF, De Swert KO, Schelfhout V, Pauwels RA (2003). The role of neural inflammation in asthma and chronic obstructive pulmonary disease. Ann N Y Acad Sci 992: 218-230.
17. Kim S, Nadel JA (2004). Role of neutrophils in mucus hypersecretion in COPD and implications for therapy. Treat Respir Med 3: 147-159.
18. King M (2005). Mucus and its role in airway clearance and cytoprotection. In: Qutayba H, Shannon J, Martin JG (eds) Physiologic Basis of Respiratory Disease. BC Decker Inc: Hamilton, pp 409-416.
19. Kuo H, Rhode JAL, Tokuyama K, Barnes PJ, Rogers DF (1990). Capsaicin and sensory neuropeptide stimulation of goblet cell secretion in guinea pig trachea. J Physiol (Lond) 431: 629-641.
20. Larson SD, Schelegle ES, Hyde DM, Plopper CG (2003). The three-dimensional distribution of nerves along the entire intrapulmonary airway tree of the adult rat and the anatomical relationship between nerves and neuroepithelial bodies. Am J Respir Cell Mol Biol 28: 592-599.
21. Lee LY, Lundberg JM (1994). Capsazepine abolishes pulmonary chemoreflexes induced by capsaicin in anesthetized rats. J Appl Physiol 76: 1848-1855.
22. Lewis CA, El-Hashim AZ, Gerspacher M, Hoshiko K, Mazzoni L, Pfannkuche HJ, Subramanian N, Fozard JR (2004). The airways pharmacology of DNK333, a potent, selective, non-peptide dual NK1/NK2 receptor antagonist. Drug Dev Res 63: 161-173.
23. Liu Y-C, Khawaja AM, Rogers DF (1998). Pathophysiology of airway mucus secretion in asthma. In: Barnes PJ, Rodger IW, Thomson NC, (eds)., Third Edition Basic Mechanisms and Clinical Managaement. Academic Press: San Diego, pp 205-227.
24. Lundberg JM, Hokfelt T, Martling CR, Saria A, Cuello C (1984). Substance P-immunoreactive sensory nerves in the lower respiratory tract of various mammals including man. Cell Tissue Res 235: 251-261.
25. Maggi CA (1997). The effects of tachykinins on inflammatory and immune cells. Regul Pept 7: 75-90.
26. Mapp CE, Miotto D, Braccioni F, Saetta M, Turato G, Maestrelli P, Krause JE, Karpitskiy V, Boyd N, Geppetti P, Fabbri LM (2000). The distribution of neurokinin-1 and neurokinin-2 receptors in human central airways. Am J Respir Crit Care Med 161: 207-215.
27. McDonald DM, Mitchell RA, Gabella G, Haskell A (1988). Neurogenic inflammation in the rat trachea II. Identity and distribution of nerves mediating the increase in vascular permeability. J Neurocytol 17: 605-628.
28. Mead J (1970). The lung's 'quiet zone'. N Engl J Med 282: 1318-1319.
29. Meini S, Mak JCW, Rohde JAL, Rogers DF (1993). Tachykinin control of ferret airways: Mucus secretion, bronchoconstriction and receptor mapping. Neuropeptides 24: 81-89.
30. Melton L (2002). Does mucus hypersecretion matter in airway disease? Lancet 359: 1924.
31. Norris AA (1996). Pharmacology of sodium cromoglycate. Clin Exp Allergy 26: 5-7.
32. Page C (1994). Sodium cromoglycate, a tachykinin antagonist? Lancet 343 (8889): 70.
33. Patacchini R, Maggi CA (1995). Tachykinin receptors and receptor subtypes. Arch Int Pharmacodyn Ther 329: 161-184.
34. Quintana HK, Cannet C, Schaeublin E, Zurbruegg S, Sugar R, Mazzoni L, Page CP, Fozard JR, Beckmann N (2006). Identification with MRI of the pleura as a major site of the acute inflammatory effects induced by ovalbumin and endotoxin challenge in the airways of the rat. Am J Physiol Lung Cell Mol Physiol 291: L651-L657.
35. Ramnarine SI, Hirayama Y, Barnes PJ, Rogers F (1994). Sensoryefferent neural control of mucus secretion: Characterization using tachykinin receptor antagonists in ferret trachea in vitro. Br J Pharmacol 113: 1183-1190.
36. Ray NJ, Jones AJ, Keen P (1991). Morphine, but not sodium cromoglycate, modulates the release of substance P from capsaicin-sensitive neurones in the rat trachea in vitro. Br J Pharmacol 102: 797-800.
37. Reynolds PN, Holmes MD, Scicchitano L (1997). Role of tachykinins in bronchial hyper-responsiveness. Clin Exp Pharmacol Physiol 24: 273-280.
38. Rogers DF, Aursudkij B, Barnes PJ (1989). Effects of tachykinins on mucus secretion on human bronchi in vitro. Eur J Pharmacol 174: 283-286.
39. Rogers DF (1995). Neurokinin receptors subserving airways secretion. Can J Physiol Pharmacol 73: 932-939.
40. Rogers DF (1997). Neurogenic inflammation in lung disease: burn out? Inflammo Pharmacol 5: 319-329.
41. Rogers DF (2001). Motor control of airway goblet cells and glands. Resp Physiol 125: 129-144.
42. Rogers DF (2004). Airway mucus hypersecretion in asthma: an undervalued pathology? Curr Opin Pharmacol 4: 241-250.
43. Rogers DF (2005). Mucociliary dysfunction in COPD: effect of current pharmacotherapeutic options. Pulm Pharmacol Ther 18: 1-8.
44. Solway J, Leff AR (1991). Sensory neuropeptides and airway function. J Appl Physiol 71: 2077-2087.
45. Szallasi A, Blumberg PM (1999). Vanilloid (Capsaicin) receptors and mechanisms. Pharmacol Rev 51: 159-212.
46. Tigani B, Schaeublin E, Sugar R, Jackson AD, Fozard JR, Beckmann N (2002). Pulmonary inflammation monitored noninvasively by MRI in freely breathing rats. Biochem Biophys Res Commun 292: 216-221.
47. Uddman R, Luts A, Sundler F (1985). Occurrence and distribution of calcitonin gene-related peptide in the mammalian respiratory tract and middle ear. Cell Tissue Res 241: 551-555.
48. Vestbo J, Prescott E, Lange P (1996). Association of chronic mucus hypersecretion with FEV1 decline and chronic obstructive pulmonary disease morbidity. Copenhagen City Heart Study Group. Am J Respir Crit Care Med 153: 1530-1535.